Skip to content
10-Q

Quarterly Report

Celldex Therapeutics, Inc. CLDX

0001104659-26-057113

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 78.49M sh
Shares Diluted Q1 2026 · Mar 31, 2026 66.57M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 66.38M sh
Capex Q1 2026 · Mar 31, 2026 $1.64M
Capex Q1 2026 · Mar 31, 2025 $265K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$65.59M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$54.37M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $35.73M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $28.87M
Stockholders Equity Q1 2026 · Mar 31, 2026 $456.23M
Stockholders Equity Q1 2026 · Dec 31, 2025 $527.17M
Stockholders Equity Q1 2026 · Mar 31, 2025 $702.98M
Stockholders Equity Q1 2026 · Dec 31, 2024 $747.01M
Current Liabilities Q1 2026 · Mar 31, 2026 $51.47M
Current Liabilities Q1 2026 · Dec 31, 2025 $50.99M
Total Liabilities Q1 2026 · Mar 31, 2026 $55.03M
Total Liabilities Q1 2026 · Dec 31, 2025 $55.82M
Current Assets Q1 2026 · Mar 31, 2026 $459.22M
Current Assets Q1 2026 · Dec 31, 2025 $534.66M
Total Assets Q1 2026 · Mar 31, 2026 $511.25M
Total Assets Q1 2026 · Dec 31, 2025 $582.98M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.18
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.81
Eps Basic Q1 2026 · Mar 31, 2026 −$1.18
Eps Basic Q1 2026 · Mar 31, 2025 −$0.81
Sga Expense Q1 2026 · Mar 31, 2026 $11.45M
Sga Expense Q1 2026 · Mar 31, 2025 $10.82M
Rd Expense Q1 2026 · Mar 31, 2026 $73M
Rd Expense Q1 2026 · Mar 31, 2025 $52.61M
Net Income Q1 2026 · Mar 31, 2026 −$78.69M
Net Income Q1 2026 · Mar 31, 2025 −$53.8M
Operating Income Q1 2026 · Mar 31, 2026 −$84.44M
Operating Income Q1 2026 · Mar 31, 2025 −$62.74M
Revenue Q1 2026 · Mar 31, 2026 $15K
Revenue Q1 2026 · Mar 31, 2025 $695K